Story preview
Continue reading on the publisher site for the full article.
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
12
in the last 3 days
First reported
2 days ago
11 outlets since
Countries
11 other outlets reported this story in the last 3 days.
Rothschild & Co Redburn increased their price objective on Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a "neutral" rating in a research report on Thursday.
Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.
Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.